Strong Clinical Demand for Affymetrix Affymetrix third quarter sales slipped 0.6% to $86.5 million but grew 3.4% excluding currency due to strong clinical demand, increased licensing revenue and further adoption in pharmaceutical markets. Overall, Consumables sales grew 2.7%, roughly 7% excluding currency, to account for 88% of revenues. Instrument sales declined 1.0% but grew in […]